CN101856434A - Application of Puer tea in preparing drugs for resisting immunosenescence or other relevant diseases - Google Patents
Application of Puer tea in preparing drugs for resisting immunosenescence or other relevant diseases Download PDFInfo
- Publication number
- CN101856434A CN101856434A CN 201010205429 CN201010205429A CN101856434A CN 101856434 A CN101856434 A CN 101856434A CN 201010205429 CN201010205429 CN 201010205429 CN 201010205429 A CN201010205429 A CN 201010205429A CN 101856434 A CN101856434 A CN 101856434A
- Authority
- CN
- China
- Prior art keywords
- tea
- folium camelliae
- camelliae assamicae
- immunosenescence
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an application of Puer tea in preparing drugs for resisting immunosenescence or other relevant diseases. The invention makes research and analysis on the anti-immunosenescence fuction and the theory thereof of the Puer tea, proves that the Puer tea or an extractive thereof has dual functions of enhancing recessive immunity and restraining excessive inflammatory reaction of an aged organism under the action of reversing aged immunocyte ( reducing memorability T cells and increasing NK cells), realizes the purpose of preventing immunosenescence, expands the application range of the Puer tea or the extractive thereof, and provides a drug or health care product for effectivly preventing and / or treating the immunosenescence or the other relevant diseases.
Description
Technical field
The present invention relates to the medicine of a kind of anti-immunosenescence or its relevant disease, be specifically related to Folium camelliae assamicae in the anti-immunosenescence of preparation or the medicine of its relevant disease or the purposes in the health product.
Background technology
Folium camelliae assamicae is as the distinctive historical famous tea in Yunnan Province, and is well-known at home and abroad with its unique processing process and health care.But the health care of Folium camelliae assamicae mostly is protracted experience greatly and sums up or folklore, lacks scientific basis.Mainly carry out for the research of Folium camelliae assamicae effect at present at non-old and feeble laboratory animal.And in actual application, Pu'er tea also has many-sided health-care effect to elderly population, and the principle of the health-care effect of elderly population is not also obtained illustrating of certain, science so far.
Immunosenescence (immunosenescence) is meant follows aging, phenomenon (the Aw D of carrying out property immune depression appears in body, Silva AB, Palmer DB.2007.Immunosenescence:emerging challenges for an ageing population.Immunology.120 (4): 435-46), it shows as elderly population and easily suffers from diseases such as infection, cancer, and to states such as prophylactic immunization hyporeactives.Though the variation of immunosenescence relates to the various kinds of cell and the factor in the body, the topmost T cells that is changed to acquired immune system (
T lymphocyte) reduces gradually with age growth, meanwhile, memory T cell (memory T lymphocyte) but gathers (Vallejo AN.2007.Immune remodeling:lessons from repertoire alterations during chronologicalaging and in immune-mediated disease.Trends Mol Med.13 (3): 94-102) in a large number.In inherent immune system, the immunocyte of keeping daily immunologic function is mainly natural killer cell, i.e. NK cell, and it is followed aging and reduces.The consequence of these variations is that the protection cell at new invasion pathogen reduces in the body; be that effective anti-infective " weapon " reduces; the result causes the anti-infection ability of elderly population to descend; cause the body inflammatory cell and the factor to increase simultaneously; be that elderly population not merely shows as immunologic hypofunction; also show the chronic inflammatory disease process; as the inflammatory factor in the blood (pro-inflammatory cytokines); level as IL-6 etc. increases (Gupta S; Agrawal A; Agrawal S, et al.2006.A paradox of immunodeficiency and inflammation inhuman aging:lessons learned from apoptosis.Immun Ageing.3:5).These inflammatory factors participate in the pathogenesis of common Senile disease.
The state that above-mentioned evidence prompting senile organism is in immunocompromised and chronic inflammatory disease and deposits, therefore simple immunostimulant or merely the antiinflammatory means may not be ideal defying age strategy.At the dual performance and the mechanism of aging, reverse old and feeble above-mentioned pathological change and may more help to improve antidotal actual effect.Do not appear in the newspapers so far from the effect of anti-immunosenescence and antiphlogistic double duty discussion Folium camelliae assamicae and extract thereof.
Summary of the invention
For the health-care effect of Folium camelliae assamicae being carried out the conclusive evidence of scientific experiments, particularly studies have shown that its health-care effect to aging and old common disease patient, the present invention is directed to Folium camelliae assamicae the old and feeble immunoloregulation function of elderly population and mechanism of action etc. have been carried out series of studies, illustrate its treatment, health care and inquire into its mechanism of action, purpose is to provide a kind of medicine or health product that effectively prevent and/or treat immunosenescence or its relevant disease.
Be used to realize that the technical scheme of above-mentioned purpose is as follows:
Folium camelliae assamicae or its extract prevent and/or treat the medicine of immunosenescence or its relevant disease or the purposes in the health product in preparation.Preferably, immunosenescence is old people's a immunosenescence.
In such use, immunosenescence or its relevant disease can be selected from anti-infection ability and descend; Cancer; The prophylactic immunization reaction descends; Chronic inflammatory disease, atherosclerosis for example, chronic inflammatory bowel disease, osteoporosis, type and chronic arthritis; And the DNA damage aging and the disease of bringing out, for example one or more in the DNA damage cancer of bringing out.Wherein, anti-infection ability descends to being specially the infection rate raising and/or infecting the order of severity increases; Chronic inflammatory bowel disease is specially Crohn disease and/or ulcerative colitis.
In such use, Folium camelliae assamicae can be given birth to tea and/or the ripe tea of Folium camelliae assamicae for Folium camelliae assamicae.Preferably, Pu'er tea is the Folium camelliae assamicae water extract.
The preparation method of Pu'er tea can comprise Folium camelliae assamicae is added the water boil after-filtration, gets filtrate.Specifically, the preparation method of Pu'er tea can may further comprise the steps:
(1) Folium camelliae assamicae is added water boil 20 minutes, the mass ratio of Folium camelliae assamicae and water is 1: 20;
(2) filter, Folium camelliae assamicae is added water boil 20 minutes again, the mass ratio of Folium camelliae assamicae and water is 1: 20;
(3) filter, Folium camelliae assamicae is added water boil 10 minutes again, the mass ratio of Folium camelliae assamicae and water is 1: 10;
(4) merging filtrate, concentrating under reduced pressure.
Said medicine can also comprise pharmaceutically acceptable carrier and/or excipient.
Experimental result of the present invention shows, Pu'er tea has the effect of the pathological state that reverses senile organism immunologic hypofunction and chronic inflammatory disease and deposit, thereby applicable to defying age immunity and by prevention, health care or the treatment of the Senile disease that old and feeble dysimmunity caused, infect comprising the prevention old people, reduce the order of severity of its infection, accelerate to infect purposes such as recovery from illness.In addition, because inflammatory factor, particularly IL-6 etc. has participated in the pathogenesis of many senile chronic inflammatory diseasess, as atherosclerosis (atherosclerosis), osteoporosis (osteoporosis), type (Type2Diabetes), chronic arthritis (chronic arthritis), Crow grace (Crohn) family name disease, ulcerative colitis (ulcerative colitis), and the present invention proves that Folium camelliae assamicae or its extract can lower the level of aged animal inflammatory factor, thereby helps prevention, health care or the treatment of above-mentioned infirmities of age.
Beneficial effect of the present invention comprises: (1) is researched and analysed the defying age immunization and the principle thereof of Folium camelliae assamicae, has expanded the range of application of Folium camelliae assamicae or its extract; (2) proved that Folium camelliae assamicae or its extract have by reversing the effect of old and feeble immunocyte (reduce memory t cell and increase the NK cell), strengthen the immunologic function that goes down, suppress the high excessively dual function of senile organism inflammatory reaction simultaneously, can realize the purpose of anti-immunosenescence.
In order to observe the defying age immunization of Folium camelliae assamicae or its extract, it is the laboratory observation animal that the present invention adopts the aged animal model-quick aging subbreed (Senescence accelerated mouse/prone, SAM-P8 system, 8 monthly ages) of generally acknowledging in the world.Adopting anti-quick aging subbreed (Senescence accelerated mouse/resistance, SAM-R1 system, 8 monthly ages) simultaneously is young contrast Mus.P is according to selecting in the world in the selection at monthly age, the main standard of R system, promptly aging degree scoring, and it is obviously outstanding that the result shows that SAM-P8 Mus aging degree when 8 monthly ages shows, and be in the between twenty and fifty stage with the SAM-R1 Mus at monthly age.
The present invention is by irritating the Pu'er tea of feeding various dose to SAM-P8 Mus (8 monthly age).After the medication one month, by using the Flow Cytometry method, in analyzing animal peripheral blood and the spleen medium-sized lymphocyte with the ratio of the immune cells involved subgroup of aging, the variation of the lymphocyte factor level relevant in the analysed for plasma simultaneously with aging.The experimental result demonstration, the initial property T cell in the quick aging Mus SAM-P8 blood (
T) shared ratio is starkly lower than aging resistance Mus SAM-R1 (young Mus) in peripheral blood lymphocyte, and the ratio of memory t cell (memory T) in peripheral blood lymphocyte is then apparently higher than aging resistance Mus SAM-R1, P＜0.001.The Folium camelliae assamicae of various dose give birth to tea and ripe tea extract all can significantly raise initial T lymphocyte in the spleen cell (
T) ratio, P＜0.05-0.001.Living tea of the Folium camelliae assamicae of various dose and ripe tea extract all can significantly reduce the lymphocytic ratio of Memorability T in the blood, P＜0.05-0.001.Ratio to the initial property T cell in the blood does not show tangible effect, P＞0.05.Gathering of the decline of T cells and memory T cell is one of notable attribute of old and feeble immunity.
In addition, natural killer cell is the main cell in the body inherent immunity system.(natural killer, NK) shared ratio is starkly lower than aging resistance Mus SAM-R1, P＜0.001 to natural killer cell in the quick aging Mus SAM-P8 blood in peripheral blood lymphocyte.The Pu'er tea of various dose all can significantly increase NK cell in the blood shared ratio in peripheral blood lymphocyte, P＜0.001.
Interleukin-6 (IL-6) is one of main inflammatory factor of body, and it participates in the pathological process of many infirmities of age inflammation.The content of inflammatory cytokine IL-6 in the quick aging Mus SAM-P8 blood is compared obviously with aging resistance Mus SAM-R1 and is increased P＜0.001.The blood serum IL-6 content of each dosage group of the living tea of Folium camelliae assamicae and each dosage group of the ripe tea of Folium camelliae assamicae significantly reduces P＜0.05-0.001.
Description of drawings
Below, describe embodiment of the present invention in conjunction with the accompanying drawings in detail, wherein:
Fig. 1: living tea of the Folium camelliae assamicae of variable concentrations and ripe tea extract are to the influence of the initial T of mouse aging SAM splenocyte (Naive T lymphocytes) cell proportion.Numerical value is all represented with the mean value standard error.###P＜0.001, SAM-P8 and SAM-R1 are relatively; * * P＜0.001, * P＜0.05, each treatment group and SAM-P8 are relatively.P8:SAM-P8 quick aging Mus; The young Mus of R1:SAM-R1 aging resistance; Living tea-low: give birth to tea low dose group 125mg/kg; Living tea-in: dosage group 250mg/kg in the tea given birth to; Give birth to tea-Gao: give birth to tea high dose group 500mg/kg; Ripe tea-low: ripe tea low dose group 125mg/kg; Ripe tea-in: dosage group 250mg/kg in the ripe tea; Ripe tea-Gao: ripe tea high dose group 500mg/kg.
Fig. 2: living tea of the Folium camelliae assamicae of variable concentrations and ripe tea extract are to the influence of mouse aging SAM peripheral blood lymphocyte memory T (Memory T lymphocytes) cell proportion.Numerical value is all represented with the mean value standard error.###P＜0.001, SAM-P8 and SAM-R1 are relatively; * * P＜0.001, * * P＜0.01, * P＜0.05, each treatment group and SAM-P8 are relatively.P8:SAM-P8 quick aging Mus; The young Mus of R1:SAM-R1 aging resistance; Living tea-low: give birth to tea low dose group 125mg/kg; Living tea-in: dosage group 250mg/kg in the tea given birth to; Give birth to tea-Gao: give birth to tea high dose group 500mg/kg; Ripe tea-low: ripe tea low dose group 125mg/kg; Ripe tea-in: dosage group 250mg/kg in the ripe tea; Ripe tea-Gao: ripe tea high dose group 500mg/kg.
Fig. 3: living tea of the Folium camelliae assamicae of variable concentrations and ripe tea extract are to mouse aging SAM spleen natural killer cell (Natural Killer, NK) effect of positive cell number purpose.Numerical value is all represented with the mean value standard error.##P＜0.01, SAM-P8 and SAM-R1 are relatively.* P＜0.05, * * P＜0.01, each treatment group and SAM-P8 comparison.P8:SAM-P8 quick aging Mus; The young Mus of R1:SAM-R1 aging resistance; Living tea-low: give birth to tea low dose group 125mg/kg; Living tea-in: dosage group 250mg/kg in the tea given birth to; Give birth to tea-Gao: give birth to tea high dose group 500mg/kg; Ripe tea-low: ripe tea low dose group 125mg/kg; Ripe tea-in: dosage group 250mg/kg in the ripe tea; Ripe tea-Gao: ripe tea high dose group 500mg/kg.
Fig. 4: living tea of the Folium camelliae assamicae of variable concentrations and ripe tea extract are to mouse aging SAM peripheral blood natural killer cell (Natural Killer, NK) effect of cell number.Numerical value is all represented with the mean value standard error.###P＜0.001, SAM-P8 and SAM-R1 are relatively.* * P＜0.001, each treatment group and SAM-P8 are relatively.P8:SAM-P8 quick aging Mus; The young Mus of R1:SAM-R1 aging resistance; Living tea-low: give birth to tea low dose group 125mg/kg; Living tea-in: dosage group 250mg/kg in the tea given birth to; Give birth to tea-Gao: give birth to tea high dose group 500mg/kg; Ripe tea-low: ripe tea low dose group 125mg/kg; Ripe tea-in: dosage group 250mg/kg in the ripe tea; Ripe tea-Gao: ripe tea high dose group 500mg/kg.
Fig. 5: living tea of the Folium camelliae assamicae of variable concentrations and ripe tea extract are to the effect of inflammatory factor IL-6 level in the mouse aging SAM blood.Numerical value is all represented with means standard deviation.###P＜0.001, SAM-P8 and SAM-R1 are relatively.* P＜0.05, * * * P＜0.001, each treatment group and SAM-P8 comparison.P8:SAM-P8 quick aging Mus; The young Mus of R1:SAM-R1 aging resistance; Living tea-low: give birth to tea low dose group 125mg/kg; Living tea-in: dosage group 250mg/kg in the tea given birth to; Give birth to tea-Gao: give birth to tea high dose group 500mg/kg; Ripe tea-low: ripe tea low dose group 125mg/kg; Ripe tea-in: dosage group 250mg/kg in the ripe tea; Ripe tea-Gao: ripe tea high dose group 500mg/kg.
The specific embodiment
Below in conjunction with the specific embodiment the present invention is further described in detail, the embodiment that provides is only in order to illustrate the present invention, rather than in order to limit the scope of the invention.
The preparation of embodiment 1 Folium camelliae assamicae water extract
Get Folium camelliae assamicae respectively and give birth to tea or ripe tea, be ground into coarse powder.Boiling water lixiviate three times, the mass ratio of Folium Camelliae sinensis and water was respectively 1: 20; 1: 20; 1: 10; Extraction time was respectively 20 minutes, 20 minutes, 10 minutes.Merging filtrate, 60 ℃ of concentrating under reduced pressure get the millet paste concentrated solution.With millet paste concentrated solution bottling sterilization (120 ℃, 20 minutes), deepfreeze (4 ℃) is standby, or extracting solution is got Pu'er tea through vacuum drying.
The pharmacology activity research of embodiment 2 Pu'er teas
1. experiment medicine:
The preparation technology of Pu'er tea is referring to embodiment 1.
2. laboratory animal:
Laboratory animal is selected aged animal model-quick aging subbreed (the Senescenceaccelerated mouse/prone that generally acknowledges in the world for use, SAM-P8, male, 8 monthly ages), adopt anti-quick aging subbreed (Senescence accelerated mouse/resistance, SAM-R1, male, 8 monthly ages) be young contrast Mus.Feed by oral filling, the Folium camelliae assamicae that gives quick aging Mus SAM-P8 various dose is respectively given birth to tea extract and the ripe tea extract of Folium camelliae assamicae, anti-quick aging subbreed (young control) and quick aging subbreed (aged control) are irritated stomach equivalent distilled water, 4 weeks of continuous use every day.
3. experimental technique:
After 4 weeks of medication, the animal via etherization, eye socket is got blood, anticoagulant heparin.With part anticoagulant heparin blood centrifugal (3000rpm, 30 minutes).Get the blood plasma branch and install in the EP pipe, divide 2 pipes, every pipe 100 μ l place-60 ℃ of refrigerators to preserve.By flow cytometer FACS Calibur TM (BDBiosciences, San Diego, CA, USA) adopt the fluidic cell microsphere to catch the blood plasma lymphokine IFN-γ of chip technology CBA (Cytometric Bead Array) synchronous detecting and old and feeble inflammation-related, TNF-α, IL-6, MCP-1 and anti-inflammatory factors IL-12p70, IL-10 etc.
By the lymphocytic cell surface antibody labeling peripheral blood of employing specificity fluorescent labelling and the lymphocyte of spleen, the lymphocyte subgroup to blood and spleen carries out flow cytometry then.Cell in the blood is shaken up, place the special-purpose test tube of BD streaming respectively.Every pipe 100 μ l, each pipe adds the antibody of corresponding lymphocytic cell surface labelling.After the room temperature lucifuge was hatched 30 minutes, every pipe added erythrocyte cracked liquid 1ml, abundant mixing, room temperature lucifuge 5 minutes.Centrifugal 1500 rev/mins, 5 minutes, abandon supernatant.Sedimentation cell is given a baby a bath on the third day after its birth time with PBS.All sedimentary cell suspensions are got up, and usefulness U.S. FACS Caliber flow cytometer (FACS Calibur TM, BD Biosciences, San Diego, CA USA) goes up machine lymphocyte subgroup is carried out streaming detection and analysis.
4. experimental result:
Living tea of the Folium camelliae assamicae of variable concentrations or ripe tea extract are to the influence of initial T (Naive T lymphocytes) cell proportion in the mouse aging SAM splenocyte.The minimizing of T cells is one of notable attribute of old and feeble immunity, also is the main cause that causes old and feeble immunologic function to go down.Initial property T cell in this experimental result demonstration quick aging Mus SAM-P8 splenocyte (
T) shared ratio is starkly lower than aging resistance Mus SAM-R1 (young Mus), P＜0.001 in splenocyte.The Folium camelliae assamicae of various dose is given birth to tea or ripe tea extract all can significantly improve in the splenocyte
The ratio of T cell, P＜0.05-0.001 is referring to Fig. 1.
Pu'er tea is to the influence of memory t cell (MemoryT cell) in quick aging Mus (SAM-P8) blood.It is the notable attribute of old and feeble immunity that memory T cell gathers, and also is the one of the main reasons that causes immunosenescence.The ratio of memory t cell (memory T) in peripheral blood lymphocyte in this experimental result demonstration quick aging Mus SAM-P8 blood is apparently higher than aging resistance Mus SAM-R1, P＜0.001.The ripe tea extract of Folium camelliae assamicae of living tea extract of the Folium camelliae assamicae of basic, normal, high dosage and basic, normal, high dosage all can significantly reduce the ratio of the memory T cell in the blood, and P＜0.05-0.001 is referring to Fig. 2.
Pu'er tea is to natural killer cell in the quick aging mice spleen cell (natural killer, influence NK).Natural killer cell is the main cell in the body inherent immunity system.(natural killer, NK) shared ratio is starkly lower than aging resistance Mus SAM-R1, P＜0.01 to natural killer cell in the quick aging Mus SAM-P8 splenocyte in splenocyte.The Folium camelliae assamicae of middle and high dosage is given birth to tea or ripe tea extract all can significantly improve NK cell in the spleen shared ratio in splenocyte, and P＜0.05-0.01 is referring to Fig. 3.
Pu'er tea is to natural killer cell (natural killer, influence NK) in the quick aging Mus peripheral blood.Natural killer cell is the main cell in the body inherent immunity system.(natural killer, NK) shared ratio is starkly lower than aging resistance Mus SAM-R1, P＜0.001 to natural killer cell in the quick aging Mus SAM-P8 blood in peripheral blood lymphocyte.The Pu'er tea of various dose all can significantly increase NK cell in the blood shared ratio in peripheral blood lymphocyte, and P＜0.001 is referring to Fig. 4.
Pu'er tea is to quick aging Mus serum interleukin-6 (Interleukin-6, IL-6) influence of content.IL-6 is one of main inflammatory factor of body, participates in the pathological process of many infirmities of age inflammation.The content of the inflammatory cytokine interleukin-6 in the quick aging Mus SAM-P8 blood obviously increases P＜0.001 than young Mus SAM-R1.The Pu'er tea of various dose can significantly reduce the content of blood serum IL-6, and P＜0.05-0.001 is referring to Fig. 5.
Claims (9)
1. Folium camelliae assamicae or its extract prevent and/or treat the medicine of immunosenescence or its relevant disease or the purposes in the health product in preparation.
2. purposes according to claim 1 is characterized in that, described immunosenescence is old people's a immunosenescence.
3. purposes according to claim 1 and 2 is characterized in that, described immunosenescence or its relevant disease are selected from anti-infection ability and descend; Cancer; The prophylactic immunization reaction descends; Chronic inflammatory disease, atherosclerosis for example, chronic inflammatory bowel disease, osteoporosis, type and chronic arthritis; And the DNA damage aging and the disease of bringing out, for example one or more in the DNA damage cancer of bringing out.
4. according to each described purposes in the claim 1 to 3, it is characterized in that described anti-infection ability drops to the infection rate raising and/or infects the order of severity to be increased; Described chronic inflammatory bowel disease is disease Crohn disease and/or ulcerative colitis.
5. according to each described purposes in the claim 1 to 4, it is characterized in that described Folium camelliae assamicae is that Folium camelliae assamicae is given birth to tea and/or the ripe tea of Folium camelliae assamicae.
6. according to each described purposes in the claim 1 to 5, it is characterized in that described Pu'er tea is the Folium camelliae assamicae water extract.
7. according to each described purposes in the claim 1 to 6, it is characterized in that the preparation method of described Pu'er tea comprises Folium camelliae assamicae is added the water boil after-filtration, gets filtrate.
8. according to each described purposes in the claim 1 to 7, it is characterized in that the preparation method of described Pu'er tea may further comprise the steps:
(1) Folium camelliae assamicae is added water boil 20 minutes, the mass ratio of Folium camelliae assamicae and water is 1: 20;
(2) filter, Folium camelliae assamicae is added water boil 20 minutes again, the mass ratio of Folium camelliae assamicae and water is 1: 20;
(3) filter, Folium camelliae assamicae is added water boil 10 minutes again, the mass ratio of Folium camelliae assamicae and water is 1: 10;
(4) merging filtrate, concentrating under reduced pressure.
9. according to each described purposes in the claim 1 to 8, it is characterized in that described pharmaceutical pack contains pharmaceutically acceptable carrier and/or excipient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010205429 CN101856434A (en) | 2010-06-22 | 2010-06-22 | Application of Puer tea in preparing drugs for resisting immunosenescence or other relevant diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010205429 CN101856434A (en) | 2010-06-22 | 2010-06-22 | Application of Puer tea in preparing drugs for resisting immunosenescence or other relevant diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101856434A true CN101856434A (en) | 2010-10-13 |
Family
ID=42942738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010205429 Pending CN101856434A (en) | 2010-06-22 | 2010-06-22 | Application of Puer tea in preparing drugs for resisting immunosenescence or other relevant diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101856434A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083664A (en) * | 2013-03-01 | 2013-05-08 | 中国医学科学院医学生物学研究所 | Puer tea immune adjuvant and application thereof in influenza vaccines |
| CN113041305A (en) * | 2021-03-03 | 2021-06-29 | 云南农业大学 | Application of deonic acid tea extract in anti-aging drugs |
| US20220409689A1 (en) * | 2021-06-29 | 2022-12-29 | Kyong-Won CHONG | Composition for preventing and treating inflammatory bowel disease including puer tea extract |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101411781A (en) * | 2008-11-21 | 2009-04-22 | 普洱市人民政府茶产业发展办公室科技服务中心 | Use of pu'er tea in preparing medicament for treating or preventing diabetes |
-
2010
- 2010-06-22 CN CN 201010205429 patent/CN101856434A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101411781A (en) * | 2008-11-21 | 2009-04-22 | 普洱市人民政府茶产业发展办公室科技服务中心 | Use of pu'er tea in preparing medicament for treating or preventing diabetes |
Non-Patent Citations (1)
| Title |
|---|
| 《精品（健康）》 20070228 博海堂 普洱茶的功效 摘要 , 第2期 2 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083664A (en) * | 2013-03-01 | 2013-05-08 | 中国医学科学院医学生物学研究所 | Puer tea immune adjuvant and application thereof in influenza vaccines |
| CN103083664B (en) * | 2013-03-01 | 2014-05-14 | 中国医学科学院医学生物学研究所 | Puer tea immune adjuvant and application thereof in influenza vaccines |
| CN113041305A (en) * | 2021-03-03 | 2021-06-29 | 云南农业大学 | Application of deonic acid tea extract in anti-aging drugs |
| US20220409689A1 (en) * | 2021-06-29 | 2022-12-29 | Kyong-Won CHONG | Composition for preventing and treating inflammatory bowel disease including puer tea extract |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guo et al. | Astragalus polysaccharide and sulfated epimedium polysaccharide synergistically resist the immunosuppression | |
| Qin et al. | Selenylation modification can enhance immune-enhancing activity of Chinese angelica polysaccharide | |
| Guan et al. | Adjuvant effects of salidroside from Rhodiola rosea L. on the immune responses to ovalbumin in mice | |
| TWI733987B (en) | Powder having function on improving immunity and the preparation method thereof | |
| CN1730015A (en) | Honey suckle extract and its preparing process and application | |
| CN101129455B (en) | Sophora extractive and method of preparing the same and application of the same | |
| CN101856434A (en) | Application of Puer tea in preparing drugs for resisting immunosenescence or other relevant diseases | |
| CN101744794A (en) | New natural hypericin antiviral drug | |
| CN102805767A (en) | Heat stranguria removal granule raw material polygonum capitatum extract with anti-gonococcus effect | |
| CN105726583A (en) | Preparation method of anti-inflammation active ingredient of artificially cultured phellinus igniarius extract | |
| CN103356812B (en) | A kind of Radix Wikstroemae granule | |
| CN101590036B (en) | Application of epoxydiene taken as inhibitor of proinflammatory mediators | |
| CN105056121A (en) | Radix rubiae-containing traditional Chinese medicine composition used for preventing eimeria tenella disease | |
| CN1330359C (en) | Chinese medicine preparation for treating AIDS and process thereof | |
| CN104688727A (en) | Application of artesunate in preparing medicine for treating middle-late sepsis | |
| CN105920083A (en) | Application of Yupingfengsan to immunity improvement | |
| Guo et al. | Effects of polysaccharide on chicks co-infected with Bordetella avium and Avian leukosis virus | |
| CN102397458A (en) | Medicinal composition for treating senile pneumonia and preparation method thereof | |
| CN104547898A (en) | Formula of eimeria tenella disease resistant traditional Chinese medicine with fresh bamboo juice as main ingredient | |
| CN111000919A (en) | Application of ethanol extract of evodia lepta in preparation of medicine for treating sepsis | |
| CN1233358C (en) | Method for extractings ubstance resisting respiratory syncytial virus from patrinia | |
| CN103816199B (en) | A kind of anti-duck virus hepatitis Chinese medical extract compound | |
| CN101411796B (en) | Novel use of betelnut and extract thereof in preparing anti-AIDS medicament | |
| CN104666295B (en) | Application of alantolactone in preparation of medicines for resisting cryptosporidium parvum | |
| CN103356717B (en) | Rhizoma Dryopteris Crassirhizomatis extract and its use in preparation of viral disease controlling medicines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20101013 |